Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study

C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I

(2012) W. Reinisch et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population

(2012) Christina Ha et al.   Clinical Gastroenterology and Hepatology

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease

(2011) Matthias Jürgens et al.   Clinical Gastroenterology and Hepatology

Safety of infliximab in 10 years of clinical practice

(2011) Sarah OʼDonnell et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis

(2011) Jean Frédéric Colombel et al.   GASTROENTEROLOGY

Genetics of inflammatory bowel disease in Asia: Systematic review and meta-analysis

(2011) Siew C. Ng et al.   INFLAMMATORY BOWEL DISEASES

Infliximab or cyclosporine for acute severe ulcerative colitis: A retrospective analysis

(2011) Kathryn E Dean et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy and Hospitalization

(2010) Abderrahim Oussalah et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Disease Activity, ANCA and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis

(2010) Matthias Jürgens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines

(2010) Andrea Walch et al.   Journal of Crohns & Colitis

Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals

(2010) Christian Mortensen et al.   Journal of Crohns & Colitis

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab

(2009) William J. Sandborn et al.   GASTROENTEROLOGY

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT

Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease

(2008) R. PANACCIONE et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study

(2008) M Henriksen et al.   GUT

European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis

(2008) E.F. Stange et al.   Journal of Crohns & Colitis

Long-term outcome after infliximab for refractory ulcerative colitis

(2008) Marc Ferrante et al.   Journal of Crohns & Colitis

Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: A KASID study

(2007) Suk-Kyun Yang et al.   INFLAMMATORY BOWEL DISEASES